| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Michael H Shani. LIMITATIONS OF CURRENT APPROACHES FOR THE TREATMENT OF ACROMEGALY. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. vol 22. issue 2. 2016-07-29. PMID:26437214. |
surgery, medical therapy, and radiotherapy are currently available treatment approaches for patients with acromegaly, with overall therapeutic goals of lowering gh levels and achieving normal igf-1 levels, reducing tumor size, improving comorbidities, and minimizing mortality risk. |
2016-07-29 |
2023-08-13 |
Not clear |
| Elena A Christofide. Clinical importance of achieving biochemical control with medical therapy in adult patients with acromegaly. Patient preference and adherence. vol 10. 2016-07-29. PMID:27471378. |
in acromegaly, achieving biochemical control (growth hormone [gh] level <1.0 ng/ml and age- and sex-normalized levels of insulin-like growth factor 1 [igf-1]) through timely diagnosis and appropriate treatment provides an opportunity to improve patient outcomes. |
2016-07-29 |
2023-08-13 |
Not clear |
| Elena A Christofide. Clinical importance of achieving biochemical control with medical therapy in adult patients with acromegaly. Patient preference and adherence. vol 10. 2016-07-29. PMID:27471378. |
in this review, the clinical impact of elevated gh and igf-1 levels, the effectiveness of current therapies, and the potential role of novel treatments for acromegaly will be discussed. |
2016-07-29 |
2023-08-13 |
Not clear |
| Elena A Christofide. Clinical importance of achieving biochemical control with medical therapy in adult patients with acromegaly. Patient preference and adherence. vol 10. 2016-07-29. PMID:27471378. |
clinical burden of acromegaly and benefits associated with management of gh and igf-1 levels will be reviewed. |
2016-07-29 |
2023-08-13 |
Not clear |
| Philippe Chanson, Sylvie Salenave, Peter Kamenick. Acromegaly. Handbook of clinical neurology. vol 124. 2016-07-28. PMID:25248589. |
acromegaly is due to excessive production of growth hormone (gh), generally by a pituitary gh-secreting adenoma. |
2016-07-28 |
2023-08-13 |
Not clear |
| b' S G\\xc4\\x83loiu, C Poian\\xc4\\x8. Current therapies and mortality in acromegaly. Journal of medicine and life. vol 8. issue 4. 2016-07-25. PMID:26664461.' |
acromegaly is a rare disease most frequently due to a gh secreting pituitary adenoma. |
2016-07-25 |
2023-08-13 |
Not clear |
| S Cannavo, F Bogazzi, A Colao, L De Marinis, P Maffei, R Gomez, E Graziano, M Monterubbianesi, S Grottol. Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience. Journal of endocrinological investigation. vol 38. issue 10. 2016-06-17. PMID:25916431. |
gh receptor antagonist pegvisomant is indicated for treatment of patients with resistant acromegaly. |
2016-06-17 |
2023-08-13 |
Not clear |
| Susan L Samso. Pasireotide in Acromegaly: An Overview of Current Mechanistic and Clinical Data. Neuroendocrinology. vol 102. issue 1-2. 2016-06-07. PMID:25792118. |
acromegaly is an insidious neuroendocrine disorder caused by hypersecretion of growth hormone (gh) by a somatotroph adenoma. |
2016-06-07 |
2023-08-13 |
Not clear |
| Shlomo Melme. New therapeutic agents for acromegaly. Nature reviews. Endocrinology. vol 12. issue 2. 2016-05-31. PMID:26610414. |
the currently available somatostatin receptor ligands (srls) and growth hormone (gh) antagonists are used to control levels of gh and insulin-like growth factor 1 (igf-1) in patients with acromegaly. |
2016-05-31 |
2023-08-13 |
Not clear |
| Shlomo Melme. New therapeutic agents for acromegaly. Nature reviews. Endocrinology. vol 12. issue 2. 2016-05-31. PMID:26610414. |
a phase iii trial of oral octreotide capsules demonstrated that this treatment can safely sustain suppressed levels of gh and igf-1 and reduce the severity of symptoms in patients with acromegaly previously controlled by injectable srl therapy, with the added benefit of no injection-site reactions. |
2016-05-31 |
2023-08-13 |
Not clear |
| Shlomo Melme. New therapeutic agents for acromegaly. Nature reviews. Endocrinology. vol 12. issue 2. 2016-05-31. PMID:26610414. |
phase i and phase ii trials of the pan-selective srl dg3173, the liquid crystal octreotide depot cam2029 and an antisense oligonucleotide directed against the gh receptor have shown that these agents can be used to achieve biochemical suppression in acromegaly and have favourable safety profiles. |
2016-05-31 |
2023-08-13 |
Not clear |
| M R Mykytyu. [CLINICAL, BIOCHEMICAL AND HORMONAL PREDICTORS OF LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH ACROMEGALY]. Likars'ka sprava. issue 5-6. 2016-05-05. PMID:27089713. |
influence of gh and igf-1 on the formation of lvh-mediated through anthropometric parameters and levels of systolic and diastolic blood pressure, which are predictors in patients with acromegaly lvh. |
2016-05-05 |
2023-08-13 |
Not clear |
| A Valea, M Carsote, C Ghervan, C Georgesc. Glycemic profile in patients with acromegaly treated with somatostatin analogue. Journal of medicine and life. vol 8 Spec Issue. 2016-05-02. PMID:26361517. |
the growth hormone (gh) excess displayed in acromegaly induces insulin resistance up to diabetes mellitus (dm). |
2016-05-02 |
2023-08-13 |
Not clear |
| F Ceccato, E Bernkopf, C Scaron. Sleep apnea syndrome in endocrine clinics. Journal of endocrinological investigation. vol 38. issue 8. 2016-04-20. PMID:26122486. |
the incidence of osas in acromegaly is high, though gh treatments seem to be unrelated to the onset of apnea in gh-deficient individuals. |
2016-04-20 |
2023-08-13 |
Not clear |
| Michael Sheppard, Marcello D Bronstein, Pamela Freda, Omar Serri, Laura De Marinis, Luciana Naves, Liudmila Rozhinskaya, Karina Hermosillo Reséndiz, Matthieu Ruffin, YinMiao Chen, Annamaria Cola. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study. Pituitary. vol 18. issue 3. 2016-04-07. PMID:25103549. |
pasireotide lar maintains inhibition of gh and igf-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, phase iii study. |
2016-04-07 |
2023-08-13 |
Not clear |
| Michael Sheppard, Marcello D Bronstein, Pamela Freda, Omar Serri, Laura De Marinis, Luciana Naves, Liudmila Rozhinskaya, Karina Hermosillo Reséndiz, Matthieu Ruffin, YinMiao Chen, Annamaria Cola. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study. Pituitary. vol 18. issue 3. 2016-04-07. PMID:25103549. |
a large, randomized, double-blind, phase iii core study demonstrated that pasireotide lar was significantly superior to octreotide lar at providing gh <2.5 μg/l and normalized igf-1 after 12 months' treatment in patients with acromegaly. |
2016-04-07 |
2023-08-13 |
Not clear |
| Mesut Ozkaya, Zeynel Abidin Sayiner, Gurkan Kiran, Kamile Gul, Ibrahim Erkutlu, Umut Elbog. Ectopic acromegaly due to a growth hormone-secreting neuroendocrine-differentiated tumor developed from ovarian mature cystic teratoma. Wiener klinische Wochenschrift. vol 127. issue 11-12. 2016-03-22. PMID:25869762. |
acromegaly is a clinical syndrome caused by the overproduction of growth hormone (gh) and also known as a rare disease. |
2016-03-22 |
2023-08-13 |
Not clear |
| Mesut Ozkaya, Zeynel Abidin Sayiner, Gurkan Kiran, Kamile Gul, Ibrahim Erkutlu, Umut Elbog. Ectopic acromegaly due to a growth hormone-secreting neuroendocrine-differentiated tumor developed from ovarian mature cystic teratoma. Wiener klinische Wochenschrift. vol 127. issue 11-12. 2016-03-22. PMID:25869762. |
biochemical diagnosis of acromegaly was made by measuring insulin-like growth factor-1 (igf-1) level and glucose-suppressed gh estimation. |
2016-03-22 |
2023-08-13 |
Not clear |
| Marie-Laure Persechini, Isabelle Gennero, Solange Grunenwald, Delphine Vezzosi, Antoine Bennet, Philippe Caro. Decreased IGF-1 concentration during the first trimester of pregnancy in women with normal somatotroph function. Pituitary. vol 18. issue 4. 2016-03-21. PMID:25179796. |
a decrease of insulin-like growth factor-i levels (igf-i) has been reported during the first trimester of pregnancy in women with acromegaly before the secretion of placental growth hormone (gh) progressively increases igf-1 concentration. |
2016-03-21 |
2023-08-13 |
Not clear |
| Manuel Puig Doming. Treatment of acromegaly in the era of personalized and predictive medicine. Clinical endocrinology. vol 83. issue 1. 2016-03-15. PMID:25640882. |
this review will discuss the development of a potential treatment algorithm for acromegaly addressing the biochemical control of the disease as well of its associated comorbidities, under a personalized approach based upon markers of prognostic and predictive significance, such as tumour size, mri adenoma signal, gh value after acute octreotide test, granular adenoma pattern, ki-67, somatostatin receptor phenotype, aryl hydrocarbon-interacting protein expression, gsp mutations, raf kinase activity, e-cadherin and beta-arrestin-1. |
2016-03-15 |
2023-08-13 |
Not clear |